PTC Therapeutics has received approval from the Brazilian health regulatory agency, ANVISA, for Waylivra (volanesorsen) to treat familial partial lipodystrophy (FPL).

This is marked as the first approval for Waylivra for the indication worldwide.

In 2018, the company in-licensed regional rights to the therapy from Ionis Pharmaceuticals’ wholly owned subsidiary Akcea Therapeutics to commercialise in Latin America.

Waylivra, a product of Ionis’ antisense technology, has already received approval in Brazil to treat Familial Chylomicronemia Syndrome (FCS).

It has also received conditional marketing approval in the European Union for the same indication.

The European Medicines Agency (EMA) has granted Orphan Drug Designation to Waylivra to treat FCS.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

PTC Therapeutics CEO Stuart Peltz said: “Waylivra’s approval as the first treatment for FPL is an important milestone for FPL patients in Brazil.

“This approval is another example of PTC leveraging its strong capabilities in Latin America to bring first-of-its-kind transformational therapies to patients with high unmet needs.”

The approval from the Brazilian regulatory agency for Waylivra was based on the data obtained from the Phase II/III BROADEN study, which was conducted on FPL patients.

In the study, participants treated with Waylivra had a significant reduction in triglyceride levels compared to the placebo-treated group.

At three months, the Waylivra-treated group had an 88% mean reduction from baseline in triglyceride levels compared to a 22% reduction in placebo patients.

The company stated that the statistically significant reductions in triglyceride levels were sustained for more than 12 months of treatment with Waylivra in patients with FPL.